Bionano Genomics (BNGO) Net Income towards Common Stockholders (2017 - 2025)
Historic Net Income towards Common Stockholders for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to -$8.5 million.
- Bionano Genomics' Net Income towards Common Stockholders rose 8078.24% to -$8.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.6 million, marking a year-over-year increase of 7158.19%. This contributed to the annual value of -$112.0 million for FY2024, which is 5181.92% up from last year.
- Bionano Genomics' Net Income towards Common Stockholders amounted to -$8.5 million in Q3 2025, which was up 8078.24% from -$6.9 million recorded in Q2 2025.
- Bionano Genomics' Net Income towards Common Stockholders' 5-year high stood at -$3.1 million during Q1 2025, with a 5-year trough of -$112.6 million in Q3 2023.
- In the last 5 years, Bionano Genomics' Net Income towards Common Stockholders had a median value of -$30.0 million in 2022 and averaged -$29.9 million.
- In the last 5 years, Bionano Genomics' Net Income towards Common Stockholders crashed by 25388.1% in 2023 and then soared by 9012.79% in 2025.
- Quarter analysis of 5 years shows Bionano Genomics' Net Income towards Common Stockholders stood at -$22.9 million in 2021, then tumbled by 68.53% to -$38.7 million in 2022, then dropped by 13.48% to -$43.9 million in 2023, then skyrocketed by 54.15% to -$20.1 million in 2024, then surged by 57.75% to -$8.5 million in 2025.
- Its last three reported values are -$8.5 million in Q3 2025, -$6.9 million for Q2 2025, and -$3.1 million during Q1 2025.